CL2012002032A1 - Composición farmacéutica hospedador/huesped de administración inyectable intravenosa anestésica o sedante que comprende un hospedador de ciclodextrina o su forma modificada con un huesped de fármaco anestésico esteroide neuroactivo; método para inducir o mantener la anestesia o sedación; y uso para inducir la anestesia. - Google Patents
Composición farmacéutica hospedador/huesped de administración inyectable intravenosa anestésica o sedante que comprende un hospedador de ciclodextrina o su forma modificada con un huesped de fármaco anestésico esteroide neuroactivo; método para inducir o mantener la anestesia o sedación; y uso para inducir la anestesia.Info
- Publication number
- CL2012002032A1 CL2012002032A1 CL2012002032A CL2012002032A CL2012002032A1 CL 2012002032 A1 CL2012002032 A1 CL 2012002032A1 CL 2012002032 A CL2012002032 A CL 2012002032A CL 2012002032 A CL2012002032 A CL 2012002032A CL 2012002032 A1 CL2012002032 A1 CL 2012002032A1
- Authority
- CL
- Chile
- Prior art keywords
- host
- induce
- anesthesia
- anesthetic
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Nanotechnology (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Anesthesiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29724910P | 2010-01-21 | 2010-01-21 | |
| US38531810P | 2010-09-22 | 2010-09-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2012002032A1 true CL2012002032A1 (es) | 2012-12-21 |
Family
ID=44306295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2012002032A CL2012002032A1 (es) | 2010-01-21 | 2012-07-20 | Composición farmacéutica hospedador/huesped de administración inyectable intravenosa anestésica o sedante que comprende un hospedador de ciclodextrina o su forma modificada con un huesped de fármaco anestésico esteroide neuroactivo; método para inducir o mantener la anestesia o sedación; y uso para inducir la anestesia. |
Country Status (27)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2631233C (en) | 2005-11-28 | 2011-11-08 | Marinus Pharmaceuticals | Ganaxolone formulations and methods for the making and use thereof |
| US10478505B2 (en) | 2011-09-23 | 2019-11-19 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| SG10201506273PA (en) * | 2011-11-29 | 2015-09-29 | Jurox Pty Ltd | Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug |
| PL2806877T3 (pl) * | 2012-01-23 | 2020-06-01 | Sage Therapeutics, Inc. | Formulacje neuroaktywnego steroidu zawierające kompleks allopregnanolonu i eteru sulfobutylowego beta-cyklodekstryny |
| US20140050789A1 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| RS62761B1 (sr) * | 2012-08-21 | 2022-01-31 | Sage Therapeutics Inc | Alopregnanolon za lečenje refraktornog epileptičkog statusa |
| US9757391B2 (en) | 2012-11-09 | 2017-09-12 | Goodchild Investments Pty Ltd | Neuroactive steroids and their use to facilitate neuroprotection |
| DK2925327T3 (da) * | 2012-11-30 | 2024-03-25 | Univ California | Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression |
| WO2015134670A1 (en) * | 2014-03-05 | 2015-09-11 | Mingbao Zhang | Deuterated ganaxolone derivatives |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| IL252848B2 (en) * | 2015-02-06 | 2024-07-01 | Marinus Pharmaceuticals Inc | Intravenous Genaxolone Formulations and Their Use in the Treatment of Epileptic Seizures and Other Seizure Disorders |
| MA45276A (fr) | 2015-06-18 | 2018-04-25 | Sage Therapeutics Inc | Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation |
| US9585867B2 (en) | 2015-08-06 | 2017-03-07 | Charles Everett Ankner | Cannabinod formulation for the sedation of a human or animal |
| JP2018530585A (ja) | 2015-10-16 | 2018-10-18 | マリナス ファーマシューティカルズ インコーポレイテッド | ナノ粒子を含む注射可能な神経ステロイド製剤 |
| TW202400182A (zh) | 2016-03-08 | 2024-01-01 | 美商賽吉醫療公司 | 神經活性類固醇，其組合物及用途 |
| BR112019002538A2 (pt) | 2016-08-11 | 2019-05-21 | Ovid Therapeutics Inc. | uso de uma composição farmacêutica compreendendo um modulador alostérico, uso de uma composição farmacêutica compreendendo garboxadol ou um sal farmaceuticamente aceitável do mesmo, e composição farmacêutica para a administração parenteral |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| CN111971238B (zh) | 2018-04-16 | 2022-02-18 | 川崎重工业株式会社 | 带式输送机 |
| US11472833B2 (en) | 2018-07-03 | 2022-10-18 | Drawbridge Pharmaceuticals Pty Ltd | Neuroactive steroids and methods of preparation |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| JP2022514991A (ja) * | 2018-12-10 | 2022-02-16 | ハロー・サイエンス・エル・エル・シー | 安定な麻酔薬製剤および関連する剤形 |
| CA3145923A1 (en) | 2019-08-05 | 2021-02-11 | David Czekai | Ganaxolone for use in treatment of status epilepticus |
| CN119950517A (zh) | 2019-12-06 | 2025-05-09 | 马瑞纳斯制药公司 | 用于治疗结节性硬化症的加奈索酮 |
| US11969434B1 (en) | 2022-08-29 | 2024-04-30 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
| US12186327B2 (en) | 2022-08-29 | 2025-01-07 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE100712T1 (de) * | 1989-05-24 | 1994-02-15 | Innovet Inc | Hypoallergene anaesthesierende/hypnotische steroide arzneizubereitung. |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| WO1993017711A1 (en) | 1992-03-11 | 1993-09-16 | Australian Commercial Research & Development Limited | New cyclodextrins and new formulated drugs |
| US5472954A (en) * | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
| JP4227675B2 (ja) * | 1996-10-25 | 2009-02-18 | 康武 日地 | 神経毒軽減麻酔剤 |
| AUPQ633900A0 (en) * | 2000-03-20 | 2000-04-15 | Jurox Pty Ltd | Anaesthetic composition |
| RU2288921C2 (ru) * | 2000-12-19 | 2006-12-10 | Калифорниа Инститьют оф Текнолоджи | Композиции, содержащие комплексы включения |
| US7034013B2 (en) * | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| JP4334229B2 (ja) * | 2001-03-20 | 2009-09-30 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | プロポフォール及びスルホアルキルエーテルシクロデキストリン含有製剤 |
| IL152575A (en) * | 2002-10-31 | 2008-12-29 | Transpharma Medical Ltd | A skin-to-skin transmission system of water-insoluble drugs |
| CA2631233C (en) * | 2005-11-28 | 2011-11-08 | Marinus Pharmaceuticals | Ganaxolone formulations and methods for the making and use thereof |
-
2011
- 2011-01-19 GB GB1210657.1A patent/GB2491491B/en active Active
- 2011-01-19 DK DK11734245.1T patent/DK2525798T3/da active
- 2011-01-19 SI SI201131342T patent/SI2525798T1/en unknown
- 2011-01-19 NZ NZ601255A patent/NZ601255A/xx not_active IP Right Cessation
- 2011-01-19 NO NO11734245A patent/NO2525798T3/no unknown
- 2011-01-19 CN CN201180013975.2A patent/CN102802635B/zh active Active
- 2011-01-19 RS RS20171135A patent/RS56576B1/sr unknown
- 2011-01-19 KR KR1020127021761A patent/KR101747476B1/ko active Active
- 2011-01-19 HR HRP20171699TT patent/HRP20171699T1/hr unknown
- 2011-01-19 PL PL11734245T patent/PL2525798T3/pl unknown
- 2011-01-19 SG SG2012050159A patent/SG181997A1/en unknown
- 2011-01-19 BR BR112012017800-8A patent/BR112012017800B1/pt active IP Right Grant
- 2011-01-19 US US13/574,201 patent/US8697678B2/en active Active
- 2011-01-19 HU HUE11734245A patent/HUE035441T2/en unknown
- 2011-01-19 JP JP2012549208A patent/JP5930311B2/ja active Active
- 2011-01-19 ES ES11734245.1T patent/ES2646829T3/es active Active
- 2011-01-19 RU RU2012134321/15A patent/RU2574022C2/ru active
- 2011-01-19 EP EP11734245.1A patent/EP2525798B1/en active Active
- 2011-01-19 GB GB1201842.0A patent/GB2484244B/en active Active
- 2011-01-19 AU AU2011207103A patent/AU2011207103B2/en active Active
- 2011-01-19 PT PT117342451T patent/PT2525798T/pt unknown
- 2011-01-19 SM SM20170518T patent/SMT201700518T1/it unknown
- 2011-01-19 WO PCT/AU2011/000050 patent/WO2011088503A1/en not_active Application Discontinuation
- 2011-01-19 CA CA2786762A patent/CA2786762C/en active Active
- 2011-01-19 LT LTEP11734245.1T patent/LT2525798T/lt unknown
-
2012
- 2012-07-18 ZA ZA2012/05370A patent/ZA201205370B/en unknown
- 2012-07-20 CL CL2012002032A patent/CL2012002032A1/es unknown
-
2013
- 2013-11-01 US US14/069,751 patent/US8975245B2/en active Active
-
2017
- 2017-11-07 CY CY20171101164T patent/CY1119947T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2012002032A1 (es) | Composición farmacéutica hospedador/huesped de administración inyectable intravenosa anestésica o sedante que comprende un hospedador de ciclodextrina o su forma modificada con un huesped de fármaco anestésico esteroide neuroactivo; método para inducir o mantener la anestesia o sedación; y uso para inducir la anestesia. | |
| CL2015002733A1 (es) | Composición farmacéutica de clorhidrato de s-cetamina. | |
| BRPI0917975A2 (pt) | formulação de depósito de formação local injetável, processo para a preparação da referida formulação, composição farmacêutica, seringa pré-carregada, e uso de peg500 dme | |
| BR112013031794A2 (pt) | novos derivados de oxintomodulina e composição farmacêutica para o tratamento da obesidade compreendendo os mesmos | |
| CL2013000801A1 (es) | Composicion farmaceutica que comprende un inhibidor de rankl y una hormona o un derivado de la misma, y uso del inhibidor rankl para preparar dicha composicion | |
| CL2013000444A1 (es) | Composicion farmaceutica oral de liberacion prolongada que comprende un material de liberacion prolongada, y oxicodona y naloxona, cuya composicion farmaceutica almacenada en condiciones de estres tiene menos de un 4% de sustancias relacionadas con oxicodona y naloxona; y uso de un aglutinante para fabricar dicha composicion. | |
| CL2011000214A1 (es) | Composicion farmaceutica que comprende progesterona micronizada y aceite de cartamo tipo ii; y uso para el tratamiento de una condicion relacionada con la insuficiencia de secrecion de progesterona. | |
| EA201390804A1 (ru) | Лекарственная форма лакозамида для приема один раз в сутки | |
| PT2341927T (pt) | Composição incluindo péptidos associados a tumores e uma vacina para o tratamento do glioblastoma e outros cancros | |
| EP2861072A4 (en) | NATURAL COMBINED HORMONRY SUB-FORMULATIONS AND THERAPIES | |
| MX2018008597A (es) | Composiciones inyectables de melfalan que comprenden un derivado de ciclodextrina y metodos de fabricacion y uso de las mismas. | |
| TN2011000471A1 (en) | Pharmaceutical composition presenting anti-inflammatory properties | |
| CL2015002534A1 (es) | Formulaciones combinadas de neosaxitoxina para una anestesia local prolongada | |
| BR112014010670A2 (pt) | composição para administração transdérmica de uma progestina, dispositivo de administração de droga transdérmica, e, método para melhorar a estabilidade de uma composição de administração transdérmica | |
| BR112013015816A2 (pt) | construção de dna para imunomodulação, composição farmacêutica, vacina e uso de uma construção de dna | |
| BR112012024673A2 (pt) | composição anestésica termogelificante | |
| IN2014MN02214A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| EP3130583C0 (en) | KYNURENINE-3-MONOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | |
| AR080550A1 (es) | Filtro con material aditivo | |
| BRPI0815821A2 (pt) | Composições e métodos que empregam antagonistas nmda para alcançar um efeito poupador de anestésico. | |
| BR112014020113A8 (pt) | Composições farmacêuticas e método para diminuir a frequência de micção | |
| BR112012020989A2 (pt) | composições veterinárias | |
| BR112013014189A8 (pt) | composição farmacêutica, uso de um agente de potencialização e uso de uma composição | |
| BR112013015085A2 (pt) | composição farmacêutica, método para preparar uma composição, e, uso de composição | |
| BRPI1010073A2 (pt) | composição anticancerígina injetável para administração local contendo hidroxicloquina |